eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive About the journal Abstracting and indexing Subscription Contact Instructions for authors
vol. 9
Original paper

Efficacy of oxycodone in sustained-release, divisible tablet in the therapy of pain prescribed by palliative medicine physicians and oncologists in daily clinical practice

Jerzy Chudek, Grzegorz Orlik, Iga Grochoła, Agnieszka Almgren-Rachtan

Medycyna Paliatywna 2017; 9(4): 218–224
Online publish date: 2018/03/08
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The aim of the study
This study aims to evaluate the efficacy of oxycodone sustained-release, divisible tablets in pain treatment in daily clinical practice.

Material and methods
Seventy-four oncologists and 34 palliative medicine physicians surveyed 1760 outpatients with pain of different aetiologies, persisting in 1198 for more than three months, treated with oxycodone sustained-release divisible tablets over three consecutive visits. Analgesic efficacy and the effect of pain on daily activities were measured using visual analogue scales. Suitability of oxycodone tablet splitting was assessed with a four-point scale.

Oxycodone sustained-release, divisible tablets were mainly used for cancer pain treatment (95.7%). Higher drug doses were recommended by palliative medicine physicians than by oncologists at baseline (47.5 ±43.7 mg vs. 43.8 ±32.6 mg; p < 0.001) and at the end of follow-up (60.9 ±53.4 mg vs. 53.1 ±38.9 mg; p < 0.001). At the beginning of follow-up, the severity of pain was comparable in patients treated by oncologists and palliative medicine physicians. During 64 ±28 days of follow-up, the efficacy of analgesic therapy increased slightly more among patients treated by palliative medicine physicians and was associated with a significantly reduced effect of pain on patients’ daily activities. The percentage of palliative medicine physicians (and their patients) who appreciated the advantage of oxycodone tablet splitting at dosage adjustment increased during follow-up. At its end, over 70% of palliative medicine physicians and oncologists, and their patients, appreciated this advantage.

Palliative medicine physicians obtain greater analgesic efficacy of oxycodone sustained-release tablets in the therapy of pain than oncologists. Oxycodone sustained-release tablet splitting for dose adjustment is appreciated by the majority of physicians and their patients.


oxycodone, chronic pain, cancer pain, divisibility of the tablet

Dobrogowski J, Krajnik M, Jassem J, Wordliczek J. Stanowisko dotyczące postępowania przeciwbólowego u chorych na nowotwory. Onkol Prak Klin 2009; 5: 55-68.
Dzierżanowski T, Ciałkowska-Rysz A. Oksykodon – lek pierwszego rzutu w leczeniu silnego bólu nowotworowego. Med Paliat 2010; 3: 123-131.
Riley J, Eisenberg E, Müller-Schwefe G i wsp. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008; 24: 175-192.
Ciałkowska-Rysz A, Dzierżanowski T. Podstawowe zasady farmakoterapii bólu u chorych na nowotwory i inne przewlekłe, postępujące, zagrażające życiu choroby. Med Paliat 2014; 6: 1-6.
Ripamonti CI, Santini D, Maranzano E i wsp. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 [Suppl 7]: vi139-54.
Caraceni A, Hanks G, Kaasa S i wsp. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68.
Jarosz J. Opieka paliatywna w onkologii. Onkol Prak Klin 2005; 1: 109-115.
van Riet-Nales DA, Doeve ME, Nicia AE i wsp. The accuracy, precision and sustainability of different techniques for tablet subdivision: breaking by hand and the use of tablet splitters or a kitchen knife. Int J Pharm 2014; 466: 44-51.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe